These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28930493)

  • 1. Effect of Comorbidity on Prostate Cancer-Specific Mortality: A Prospective Observational Study.
    Rajan P; Sooriakumaran P; Nyberg T; Akre O; Carlsson S; Egevad L; Steineck G; Wiklund NP
    J Clin Oncol; 2017 Nov; 35(31):3566-3574. PubMed ID: 28930493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study.
    Stattin P; Sandin F; Thomsen FB; Garmo H; Robinson D; Lissbrant IF; Jonsson H; Bratt O
    Eur Urol; 2017 Jul; 72(1):125-134. PubMed ID: 27481175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.
    Godtman RA; Holmberg E; Khatami A; Stranne J; Hugosson J
    Eur Urol; 2013 Jan; 63(1):101-7. PubMed ID: 22980443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.
    Rider JR; Sandin F; Andrén O; Wiklund P; Hugosson J; Stattin P
    Eur Urol; 2013 Jan; 63(1):88-96. PubMed ID: 22902040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.
    Johnston TJ; Shaw GL; Lamb AD; Parashar D; Greenberg D; Xiong T; Edwards AL; Gnanapragasam V; Holding P; Herbert P; Davis M; Mizielinsk E; Lane JA; Oxley J; Robinson M; Mason M; Staffurth J; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Kockelbergh R; Kynaston H; Prescott S; Paul A; Powell P; Rosario D; Rowe E; Donovan JL; Hamdy FC; Neal DE;
    Eur Urol; 2017 Mar; 71(3):381-388. PubMed ID: 27720537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy.
    Sooriakumaran P; Nyberg T; Akre O; Widmark A; Hamdy F; Graefen M; Carlsson S; Steineck G; Wiklund NP
    Eur Urol; 2017 Sep; 72(3):345-351. PubMed ID: 28416350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.
    Fossati N; Karnes RJ; Boorjian SA; Moschini M; Morlacco A; Bossi A; Seisen T; Cozzarini C; Fiorino C; Noris Chiorda B; Gandaglia G; Dell'Oglio P; Joniau S; Tosco L; Shariat S; Goldner G; Hinkelbein W; Bartkowiak D; Haustermans K; Tombal B; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2017 Jun; 71(6):886-893. PubMed ID: 27484843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.
    Wilt TJ; MacDonald R; Rutks I; Shamliyan TA; Taylor BC; Kane RL
    Ann Intern Med; 2008 Mar; 148(6):435-48. PubMed ID: 18252677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical recurrence after robot-assisted radical prostatectomy in a European single-centre cohort with a minimum follow-up time of 5 years.
    Sooriakumaran P; Haendler L; Nyberg T; Gronberg H; Nilsson A; Carlsson S; Hosseini A; Adding C; Jonsson M; Ploumidis A; Egevad L; Steineck G; Wiklund P
    Eur Urol; 2012 Nov; 62(5):768-74. PubMed ID: 22633365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.
    Fu AZ; Tsai HT; Haque R; Yood MU; Cassidy-Bushrow AE; Van Den Eeden SK; Keating NL; Smith MR; Zhou Y; Aaronson DS; Potosky AL
    J Urol; 2017 Jun; 197(6):1448-1454. PubMed ID: 28007467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence.
    Lee BH; Kibel AS; Ciezki JP; Klein EA; Reddy CA; Yu C; Kattan MW; Stephenson AJ
    Eur Urol; 2015 Feb; 67(2):204-9. PubMed ID: 25294696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity.
    Nepple KG; Stephenson AJ; Kallogjeri D; Michalski J; Grubb RL; Strope SA; Haslag-Minoff J; Piccirillo JF; Ciezki JP; Klein EA; Reddy CA; Yu C; Kattan MW; Kibel AS
    Eur Urol; 2013 Sep; 64(3):372-8. PubMed ID: 23506834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7.
    Fosså SD; Wiklund F; Klepp O; Angelsen A; Solberg A; Damber JE; Hoyer M; Widmark A;
    Eur Urol; 2016 Oct; 70(4):684-691. PubMed ID: 27025586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age-adjusted Charlson comorbidity index is a significant prognostic factor for long-term survival of patients with high-risk prostate cancer after radical prostatectomy: a Bayesian model averaging approach.
    Lee JY; Kang HW; Rha KH; Cho NH; Choi YD; Hong SJ; Cho KS
    J Cancer Res Clin Oncol; 2016 Apr; 142(4):849-58. PubMed ID: 26660495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score.
    Epstein JI; Zelefsky MJ; Sjoberg DD; Nelson JB; Egevad L; Magi-Galluzzi C; Vickers AJ; Parwani AV; Reuter VE; Fine SW; Eastham JA; Wiklund P; Han M; Reddy CA; Ciezki JP; Nyberg T; Klein EA
    Eur Urol; 2016 Mar; 69(3):428-35. PubMed ID: 26166626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden.
    Akre O; Garmo H; Adolfsson J; Lambe M; Bratt O; Stattin P
    Eur Urol; 2011 Sep; 60(3):554-63. PubMed ID: 21664039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study.
    Kariburyo F; Wang Y; Cheng IE; Wang L; Morgenstern D; Xie L; Meadows E; Danella J; Cher ML
    BMC Urol; 2018 Jun; 18(1):55. PubMed ID: 29866100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-risk Prostate Cancer: Identification, Management, and Outcomes.
    Moschini M; Carroll PR; Eggener SE; Epstein JI; Graefen M; Montironi R; Parker C
    Eur Urol; 2017 Aug; 72(2):238-249. PubMed ID: 28318726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.